

DY  
or a pharmaceutically acceptable salt thereof;

provided that

X and Y are not both N for the same heterocyclic ring.--

---

#### **REMARKS**

The Office Action dated June 10, 2002 has been received and carefully noted. The above amendments to the claims, and the following remarks, are submitted as a full and complete response thereto.

Claims 1-11 are pending. By this Amendment, claim 1 is canceled, claims 2-6, 8-19 and 11 are amended and new claim 12 is added. No new matter is added.

#### **§ 112, Second Paragraph, Rejection**

The Office Action rejects claims 1-4 and 6-11 under 35 U.S.C. § 112, second paragraph, as being indefinite for containing asserted informalities.

Applicants believe that this rejection is overcome with the above amendments to the claims, and in particular with the addition of new claim 12 which does not include the terminology objected to. Reconsideration and withdrawal of the rejection of claims 1-4 and 6-11 under 35 U.S.C. § 112, second paragraph, are respectfully requested.

### **Objections to Claims**

The Office Action objects to claim 5 for containing an asserted informality which is corrected in the above amendment to claim 5. Reconsideration and withdrawal of the objection to claim 5 are respectfully requested.

### **§ 103 Rejections**

The Office Action rejects claims 1-11 under 35 U.S.C. § 103(a) as being obvious over WO Patent Application 98/04524 in view of WO Patent Application 96/05196. Claims 1-11 are additionally rejected under 35 U.S.C. § 103(a) as being obvious over the same two WO patent applications and further in view of Baraldi et al. ("Synthesis and Antitumor Activity of Novel Distamycin Derivatives"). These rejections are traversed as they may apply to the amended claims.

In order to expedite prosecution of this application, Applicants have limited the scope of the claims as was discussed in Applicants' April 26, 2002 Amendment to compounds for which unexpected biological activity has been demonstrated.

None of the cited prior art references disclose or even suggest to prepare Distamycin derivatives bearing (i) an acryloyl moiety and (ii) a central polyheterocyclic chain not only constituted by pyrrole rings, (iii) wherein the first heterocycle bonded to the acryloylamido moiety is a pyrazole and (iv) with B groups corresponding to N-methylamidino or cyanamidino, with the expectation of getting compounds with a pharmacological activity superior than that of analogous compounds of the prior art bearing

a terminal B amidino group (see compound 13 of Baraldi et al., as the closest prior art compound).

Besides the above amendments to claim 1, addressed to the first heterocyclic ring and to the B group, Applicants have also limited it to the compounds wherein  $R_1$  and  $R_2$  are both hydrogen atoms.

For at least the above reasons, reconsideration and withdrawal of the rejections of claims 1-11 under 35 U.S.C. § 103(a) are respectfully requested.

### **Conclusion**

Applicants respectfully submit that this application is in condition for allowance and such action is earnestly solicited. If the Examiner believes that anything further is desirable in order to place this application in even better condition for allowance, the Examiner is invited to contact Applicants' undersigned representative at the telephone number listed below to schedule a personal or telephone interview to discuss any remaining issues.

In the event this paper is not being timely filed, Applicants respectfully petition for an appropriate extension of time. Any fees for such an extension together with any additional fees may be charged to Counsel's Deposit Account 01-2300.

Respectfully submitted,

Arent Fox Kintner Plotkin & Kahn

A handwritten signature in black ink, reading "Robert K. Carpenter". The signature is fluid and cursive, with a long horizontal stroke extending from the end of the name.

Robert K. Carpenter  
Attorney for Applicants  
Reg. No. 34,794

1050 Connecticut Ave. NW  
Suite 600  
Washington, D.C. 20036-5339  
Tel: (202) 857-6000  
Fax: (202) 638-4810

RKC:tdd

**MARKED-UP COPY OF AMENDMENTS TO CLAIMS**

2. (Amended) A compound according to claim 12 [1] wherein  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$ ,  $R_8$ ,  $R_{10}$ ,  $R_{11}$  and  $R_{12}$  are, independently from each other, hydrogen, methyl or ethyl.


3. (Three times Amended) A compound according to claim 12 [1] wherein  
 $n$  is 3 or 4;

$m$  is 1;

$R_1$  and  $R_2$  are hydrogen;

$R_3$  is chlorine or bromine;

$B$  is selected from



wherein  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$ ,  $R_8$ ,  $R_{10}$ ,  $R_{11}$  and  $R_{12}$  are, independently from each other, hydrogen or methyl; and  $R_9$  is hydrogen.

4. (Amended) A compound according to claim 12 [1] wherein the acrylamido moiety is directly linked to a pyrazole or imidazole ring.

5. (Three Times Amended) A compound selected from the group consisting of:

- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido)-pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propioncyanamidine;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N-methylamidine;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -chloroacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N-methylamidine;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -chloroacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N,N'-dimethylamidine;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N,N,N'-trimethylamidine;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propionamide;

- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido)pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N-methylamide;
- 2 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido)pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) ethylguanidine;
- 2 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -chloroacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) ethylguanidine;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido)pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propyl-N,N-dimethylamine;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido)pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propionamidoxime;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -chloroacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propionamidoxime;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido)pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-O-methylamidoxime;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -chloroacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-

carboxamido) propion-O-methylamidoxime;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propionitrile;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -chloroacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propionitrile;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propioncyanamidine;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N-methylamidine;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N,N'-dimethylamidine;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N,N,N'-trimethylamidine;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido)) pyrrole-2-carboxamido propionamide;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido)



- imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido)  
pyrrole-2-carboxamido) propion-N-methylamide;
- 2 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido)  
imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido)  
pyrrole-2-carboxamido) ethylguanidine;
- 2 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -chloroacrylamido)  
imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido)  
pyrrole-2-carboxamido) ethylguanidine;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido)  
imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido)  
pyrrole-2-carboxamido) propyl-N,N-dimethylamine;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido)  
imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido)  
pyrrole-2-carboxamido) propionamidoxime;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -chloroacrylamido)  
imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido)  
pyrrole-2-carboxamido) propionamidoxime;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido)  
imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido)  
pyrrole-2-carboxamido) propion-O-methylamidoxime;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -chloroacrylamido)  
imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido)  
pyrrole-2-carboxamido) propion-O-methylamidoxime;

- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propionitrile;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-3-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N-methylamidine;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-3-(1-methyl-3-( $\alpha$ -chloroacrylamido) pyrazole-5-carboxamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N-methylamidine;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-3-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N,N'-dimethylamidine;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-3-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N,N,N'-trimethylamidine;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-3-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N-methylamide;
- 2 - (1-methyl-4-(1-methyl-4-(1-methyl-3-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) ethylguanidine;
- 2 - (1-methyl-4-(1-methyl-4-(1-methyl-3-(1-methyl-3-( $\alpha$ -chloroacrylamido) pyrazole-5-carboxamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-

carboxamido) ethylguanidine;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-3-(1-methyl-3-( $\alpha$ -bromoacrylamido)  
pyrazole-5-carboxamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido)  
pyrrole-2-carboxamido) propionamidoxime;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-3-(1-methyl-3-( $\alpha$ -bromoacrylamido)  
pyrazole-5-carboxamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido)  
pyrrole-2-carboxamido) propionitrile;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido)  
imidazole-2-carboxamido) imidazole-2-carboxamido) pyrrole-2-carboxamido)  
pyrrole-2-carboxamido) propioncyanamidine;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido)  
imidazole-2-carboxamido) imidazole-2-carboxamido) pyrrole-2-carboxamido)  
pyrrole-2-carboxamido) propion-N-methylamide;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido)  
imidazole-2-carboxamido) imidazole-2-carboxamido) pyrrole-2-carboxamido)  
pyrrole-2-carboxamido) propion-N,N-dimethylamine;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido)  
imidazole-2-carboxamido) imidazole-2-carboxamido) pyrrole-2-carboxamido)  
pyrrole-2-carboxamido) propion-O-methylamidoxime;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido)  
imidazole-2-carboxamido) imidazole-2-carboxamido) pyrrole-2-carboxamido)  
pyrrole-2-carboxamido) propionitrile;

3 - (1-methyl-3-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) pyrrole-

- 2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrazole-5-carboxamido) propion-N-methylamidine;
- 3 - (1-methyl-3-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrazole-5-carboxamido) propion-N,N'-dimethylamidine;
- 2 - (1-methyl-3-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrazole-5-carboxamido) ethylguanidine;
- 3 - (1-methyl-3-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrazole-5-carboxamido) propionamidoxime;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) imidazole-2-carboxamido) propion-N-methylamidine;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) imidazole-2-carboxamido) propionamide;
- 2 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) imidazole-2-carboxamido) ethylguanidine;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) imidazole-2-carboxamido) propionamidoxime;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N-methylamidine;

3 - (1 methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N,N'-dimethylamidine;

[2-(1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) ethylguanidine;]

2-(1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) ethylguanidine;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propionamidoxime;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propionitrile;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propioncyanamidine;

- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N-methylamidine;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -chloroacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N-methylamidine;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N,N'-dimethylamidine;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N,N,N'-trimethylamidine;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propionamide;
- 2 - (1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) ethylguanidine;
- 2 - (1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -chloroacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) ethylguanidine;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propionamidoxime;
- 3 - (1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -chloroacrylamido)pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido)

propionamidoxime;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-3-( $\alpha$ -bromoacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propionitrile;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido)

propioncyanamidine;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N-methylamidine;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N,N'-dimethylamidine;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N,N,N'-trimethylamidine;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propionamide;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N-methylamide;

2 - (1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) ethylguanidine;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) imidazole-2-

carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N,N-dimethylamine;


3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propionamidoxime;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-O-methylamidoxime;

3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-( $\alpha$ -bromoacrylamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propionitrile; and the pharmaceutically acceptable salts thereof.

6. (Twice amended) A process for preparing a compound as defined in claim 12 [1], which process comprises:

(a) reacting a compound of formula:




wherein n, m, and B are as defined in claim 1;

p is 0 or 1;

with a compound of formula:






wherein  $R_1$ ,  $R_2$ , and  $R_3$ , are as defined in claim 1;

$p$  is as defined above;

$z$  is hydroxy or a leaving group;

or:

(b) when  $B$  is equal to  $-C\equiv N$ , reacting a compound of formula:



wherein  $n$ ,  $m$ ,  $R_1$ ,  $R_2$ , and  $R_3$ , are as defined above;

with succinic anhydride; and,

(c) if desired, converting a compound of formula (I) into a pharmaceutically acceptable salt thereof.

8. (Amended) A pharmaceutical composition comprising one or more

pharmaceutically acceptable carriers and/or diluents and, as the active principle, a compound as defined in claim 12 [1].

9. (Twice amended) A compound as defined in claim 12 [1] for use in a method of treatment of a human or animal body by therapy.

11. (Twice amended) A method of manufacturing a medicament for use as an antitumor agent comprising utilizing a compound as defined in claim 12 [1].